NeuroInvestment today announced the release of its February issue, which reviews the drugs available and under development for the treatment of bipolar disorder. While sometimes associated with creativity and productivity in its mildest, hypomanic stage, bipolar illness can wreak devastating havoc, and the total direct cost of bipolar illness in the US exceeds $7 billion per year, indirect costs are estimated to approach $38 billion. With over two million Americans suffering from bipolar disorder, and current drug options troubled by limited effectiveness and side effects, this has become an increasingly attractive target for the pharmaceutical industry. Several companies are seeking to find a mood stabilizer that can succeed Pfizer's (NYSE: PFE) Neurontin (gabapentin), which has surpassed $800 million in sales annually, in spite of its teratogenicity and sedative effects. The February issue also provides a comprehensive evaluation of NPS Pharmaceuticals (NASDAQ: NPSP), which has a range of development programs both within and outside the CNS area.
February 2001 Table of Contents:
Neuroscience topic: Bipolar Disorder Company Review: NPS Pharmaceuticals News, Developments, Commentary: Curis (NASDAQ: CRIS), Aegera, NeoTherapeutics Interneuron (NASDAQ: IPIC), Gliatech, Elan, Biogen, Neurobiological Technologies, Forest, Neurocrine Biosciences Recommendations Upcoming issues will review the fields of neurotrophic factors/mimetics and neural implants, including the cutting-edge area of neural stem cells for transplantion. NeuroInvestment has set the standard for reviews of the CNS pharmaceutical industry since 1995. The NeuroInvestment ŒA List' achieved a mean increase of 63%, following increases of 74% in 1999 and 35% in 1998.
NeuroInvestment is the leading publisher of independent research information regarding companies specializing in the development of therapeutics for neurological/psychiatric disorders. NeuroInvestment is published monthly. Hardcopy and/or electronic delivery available.
Subscription Rates: 3-month trial $120, Individual:1 year $420, 2 year $720. Institutional: 3-month trial $150, 1 year $590, 2 year $1020.. Outside the US/Canada add $30 for hardcopy airmail. New subscribers during February 2001 will also receive the January issue at no cost, which is the NI Annual Review of the neuropharmaceutical sector.
